Home 禄 Business 禄 Manufacturing
German drug firm invests to tap growing market
By Ding Yining |
00:59 UTC+8 October 22, 2009
|
Print Edition
Print Edition
GERMANY-BASED Boehringer Ingelheim yesterday said it will invest 100 million euros (US$149 million) on Chinese mainland to tap the pharmaceutical market.
The drug maker will expand its pharmaceutical production capacity at its plant in Shanghai's Zhangjiang High-Tech Park and set up a Chemical Competency Center.
The center will focus on developing new vaccines for viruses that are peculiar in Asia Pacific. The drug maker's investment also includes a new animal health products manufacturing facility.
"We're hoping to see a 35 percent annual sales growth in China in the next five years," said David Preston, chairman and CEO of Boehringer Ingelheim Shanghai Pharmaceutical Co. "We are relatively a late comer in the market so we have to catch up in the next few years."
The firm will also recruit an extra 500 sales personnel in China by as early as December, bringing its total employees in the country to around 1,500.
"Expanding our business in emerging markets will be our key strategy and the driving thrust for our future growth," said Engelbert C. Tjeenk Willink, member of the board of BI.
It aims to raise its market share in China to 1.48 percent by 2020 from 0.4 percent now, said IMS, a pharmaceutical consultancy.
The drug maker will expand its pharmaceutical production capacity at its plant in Shanghai's Zhangjiang High-Tech Park and set up a Chemical Competency Center.
The center will focus on developing new vaccines for viruses that are peculiar in Asia Pacific. The drug maker's investment also includes a new animal health products manufacturing facility.
"We're hoping to see a 35 percent annual sales growth in China in the next five years," said David Preston, chairman and CEO of Boehringer Ingelheim Shanghai Pharmaceutical Co. "We are relatively a late comer in the market so we have to catch up in the next few years."
The firm will also recruit an extra 500 sales personnel in China by as early as December, bringing its total employees in the country to around 1,500.
"Expanding our business in emerging markets will be our key strategy and the driving thrust for our future growth," said Engelbert C. Tjeenk Willink, member of the board of BI.
It aims to raise its market share in China to 1.48 percent by 2020 from 0.4 percent now, said IMS, a pharmaceutical consultancy.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
